LIVIVO - Search results -

Search results

Result 1 - 10 of total 55

Search options

Article ; Online: Shifting perceptions on endoscopic surveillance and timing of prophylactic gastrectomy for hereditary diffuse gastric cancer.

van Dieren, Jolanda M / van der Post, Rachel S / Bisseling, Tanya M

2023 Volume 110, Issue 9, Page(s) 1028–1029

MeSH term(s)	Humans ; Stomach Neoplasms/genetics ; Stomach Neoplasms/prevention & control ; Stomach Neoplasms/surgery ; Gastrectomy ; Mutation ; Adenocarcinoma/surgery ; Cadherins/genetics ; Genetic Predisposition to Disease ; Germ-Line Mutation ; Neoplastic Syndromes, Hereditary/surgery
Chemical Substances	Cadherins
Language	English
Publishing date	2023-06-18
Publishing country	England
Document type	Journal Article
ZDB-ID	2985-3
ISSN	1365-2168 ; 0263-1202 ; 0007-1323 ; 1355-7688
ISSN (online)	1365-2168
ISSN	0263-1202 ; 0007-1323 ; 1355-7688
DOI	10.1093/bjs/znad192
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uk I Zs.66: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Tumor-positive peritoneal cytology in patients with gastric cancer is associated with poor outcome: A nationwide study.

Van Der Sluis, Karen / Taylor, Steven N / Kodach, Liudmila L / van Dieren, Jolanda M / de Hingh, Ignace H J T / Wijnhoven, Bas P L / Verhoeven, Rob H A / Vollebergh, Marieke A / van Sandick, Johanna W

European journal of cancer (Oxford, England : 1990)

2024 Volume 199, Page(s) 113541

Abstract: Background: The clinical significance of tumor-positive peritoneal cytology (CYT+) in gastric cancer (GC) patients is unclear. This nationwide cohort study aimed to i) assess the frequency of cytological analysis at staging laparoscopy; ii) determine ... ...

Abstract	Background: The clinical significance of tumor-positive peritoneal cytology (CYT+) in gastric cancer (GC) patients is unclear. This nationwide cohort study aimed to i) assess the frequency of cytological analysis at staging laparoscopy; ii) determine the prevalence of CYT+GC; and iii) compare overall survival (OS) in CYT+ patients versus those with (PM+) and those without (PM-) macroscopic peritoneal disease. Methods: All patients diagnosed with cT1-4, cN0-2 and M0 or synchronous PM GC between 2016-2021 were identified in the Netherlands Cancer Registry database and linked to the nationwide pathology database. Results: A total of 4397 patients was included, of which 40 % underwent cytological assessment following staging laparoscopy (863/1745). The prevalence of CYT+ was 8 %. A total of 69 patients had CYT+(1.6 %), 789 (17.9 %) had PM+ and 3539 (80.5 %) had PM- disease. Hazard ratio for OS in CYT+ versus PM+ was 0.86 (95 %CI 0.64-1.17, p-value=0.338), and in PM- versus PM+0.43 (95 %CI 0.38-0.49, p-value<0.001). No survival difference was found between systemic chemotherapy versus surgical resection in CYT+ patients. Discussion: In this nationwide study, OS for gastric cancer patients with CYT+ was equally unfavorable as for those with PM+ and significantly worse as compared to those with PM-. The optimal treatment strategy has yet to be established.
MeSH term(s)	Humans ; Stomach Neoplasms/pathology ; Cohort Studies ; Cytology ; Peritoneal Lavage ; Neoplasm Staging ; Prognosis
Language	English
Publishing date	2024-01-15
Publishing country	England
Document type	Journal Article
ZDB-ID	82061-1
ISSN	1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
ISSN (online)	1879-0852
ISSN	0277-5379 ; 0959-8049 ; 0964-1947
DOI	10.1016/j.ejca.2024.113541
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 583: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Targeted vs Random Biopsies in Surveillance Endoscopy in Hereditary Diffuse Gastric Cancer Syndrome.

Van Dieren, Jolanda M / Kodach, Liudmila L / Cats, Annemieke

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

2019 Volume 18, Issue 7, Page(s) 1647–1648

MeSH term(s)	Adenocarcinoma/surgery ; Biopsy ; Gastrectomy ; Gastroscopy ; Humans ; Stomach Neoplasms/diagnosis ; Stomach Neoplasms/surgery
Language	English
Publishing date	2019-12-27
Publishing country	United States
Document type	Letter ; Comment
ZDB-ID	2119789-1
ISSN	1542-7714 ; 1542-3565
ISSN (online)	1542-7714
ISSN	1542-3565
DOI	10.1016/j.cgh.2019.12.022
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5836: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Improving diagnostic accuracy of identifying gastric cancer patients with peritoneal metastases: tumor-guided cell-free DNA analysis of peritoneal fluid.

van der Sluis, Karen / van Sandick, Johanna W / Vollebergh, Marieke A / van Dieren, Jolanda M / Hugen, Niek / Hartemink, Koen J / Veenhof, Alexander A F A / Verhoeven, Els / van den Berg, José G / Snaebjornsson, Petur / Noe, Michael / van Wezel, Tom / Boelens, Mirjam C / Kodach, Liudmila L

Oncogene

2024

Abstract: Detection of peritoneal dissemination (PD) in gastric cancer (GC) patients remains challenging. The feasibility of tumor-guided cell-free DNA (cfDNA) detection in prospectively collected peritoneal fluid (ascites and peritoneal lavage) was investigated ... ...

Abstract	Detection of peritoneal dissemination (PD) in gastric cancer (GC) patients remains challenging. The feasibility of tumor-guided cell-free DNA (cfDNA) detection in prospectively collected peritoneal fluid (ascites and peritoneal lavage) was investigated and compared to conventional cytology in 28 patients. Besides conventional cytology, next generation sequencing was performed on primary tumor DNA and cell-free DNA from peritoneal fluid. Patients were retrospectively grouped into: a positive group (with PD) and a negative group (without PD). Detectable mutations were found in the primary tumor of 68% (n = 19). Sensitivity of PD detection by tumor-guided cfDNA analysis was 91%, compared to 64% by conventional cytology. Within the positive group (n = 11), tumor-guided cfDNA was detected in all patients with ascites samples (4/4, 100%) and in 86% (6/7) of the lavage samples, opposed to 4/4 (100%) patients with ascites and 43% (3/7) with lavage by conventional cytology. Within the negative group (n = 8), conventional cytology was negative for all samples. In two patients, tumor-guided cfDNA was detected in peritoneal lavage fluid. Interestingly, these 2 patients developed PD within 6 months, suggesting a prognostic value of tumor-guided cfDNA detection. This study showed that tumor-guided cfDNA detection in peritoneal fluids of GC patients is feasible and superior to conventional cytology in detecting PD.
Language	English
Publishing date	2024-04-23
Publishing country	England
Document type	Journal Article
ZDB-ID	639046-8
ISSN	1476-5594 ; 0950-9232
ISSN (online)	1476-5594
ISSN	0950-9232
DOI	10.1038/s41388-024-03034-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2218: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Profound Immunotherapy Response in Mismatch Repair-Deficient Breast Cancer.

Kok, Marleen / Horlings, Hugo M / Snaebjornsson, Petur / Chalabi, Myriam / Schumacher, Ton N / Blank, Christian U / Linn, Sabine C / van Dieren, Jolanda

JCO precision oncology

2021 Volume 1, Page(s) 1–3

Language	English
Publishing date	2021-12-31
Publishing country	United States
Document type	Journal Article
ISSN	2473-4284
ISSN (online)	2473-4284
DOI	10.1200/PO.17.00052
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

Verschoor, Yara L / van de Haar, Joris / van den Berg, José G / van Sandick, Johanna W / Kodach, Liudmila L / van Dieren, Jolanda M / Balduzzi, Sara / Grootscholten, Cecile / IJsselsteijn, Marieke E / Veenhof, Alexander A F A / Hartemink, Koen J / Vollebergh, Marieke A / Jurdi, Adham / Sharma, Shruti / Spickard, Erik / Owers, Emilia C / Bartels-Rutten, Annemarieke / den Hartog, Peggy / de Miranda, Noel F C C /

van Leerdam, Monique E / Haanen, John B A G / Schumacher, Ton N / Voest, Emile E / Chalabi, Myriam

Nature medicine

2024

Language	English
Publishing date	2024-03-06
Publishing country	United States
Document type	Published Erratum
ZDB-ID	1220066-9
ISSN	1546-170X ; 1078-8956
ISSN (online)	1546-170X
ISSN	1078-8956
DOI	10.1038/s41591-024-02898-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4212: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 39: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The clinical impact of testing for biomarkers in gastric cancer patients: a real-world cohort.

van der Sluis, Karen / van Sandick, Johanna W / van Dieren, Jolanda M / Vollebergh, Marieke A / Grootscholten, Cecile / van den Berg, José G / Snaebjornsson, Petur / Hartemink, Koen J / Veenhof, Alexander A F A / Chalabi, Myriam / Kodach, Liudmila L

Histopathology

2023 Volume 82, Issue 6, Page(s) 826–836

Abstract: Background and aims: In gastric cancer (GC), HER2 was the first biomarker for guided therapy registered for clinical use. Considering the recent approvals of immune check-point blockade (ICB) in gastro-oesophageal cancers, testing for mismatch repair ... ...

Abstract	Background and aims: In gastric cancer (GC), HER2 was the first biomarker for guided therapy registered for clinical use. Considering the recent approvals of immune check-point blockade (ICB) in gastro-oesophageal cancers, testing for mismatch repair deficiency (dMMR), Epstein-Barr virus (EBV) and PD-L1 combined positive score (CPS) is becoming increasingly important. Here we describe a real-world cohort on biomarker assessment in GC patients. Methods: Patients diagnosed with GC between 2017 and 2021 were included. Biomarker results were retrieved from electronic patient files. PD-L1 CPS was determined retrospectively on dMMR and EBV-positive (EBV+) tumours. Data on genomic sequencing were analysed separately. Results: Of 363 patients identified, 45% had metastatic disease. In 335 patients (92%) at least one biomarker was tested. The prevalence of HER2+, dMMR and EBV+ tumours was 10% (32 of 319), 7% (20 of 294) and 1% (three of 235), respectively. Of the dMMR and EBV+ tumours, 95% had a PD-L1 CPS ≥ 5. Therapeutic strategy was adjusted in 31 of 55 patients and consisted of anti-HER2 therapies as well as ICB in clinical trials. Genomic alterations were found in 44 of 60 tested patients. TP53 (73%) and PIK3CA (20%) mutations were most common, followed by KRAS mutations (11%) and amplifications (11%). Conclusions: In this real-world cohort, testing for HER2, dMMR and EBV status affected treatment decisions in 56% of the patients. Although most dMMR and EBV+ tumours had a PD-L1 CPS ≥ 5, not all patients with a high probability of treatment response are identified. Based on these results, a stepwise diagnostic strategy is proposed.
MeSH term(s)	Humans ; Stomach Neoplasms/genetics ; Epstein-Barr Virus Infections/complications ; Herpesvirus 4, Human/genetics ; Biomarkers, Tumor/genetics ; Retrospective Studies ; B7-H1 Antigen/genetics
Chemical Substances	Biomarkers, Tumor ; B7-H1 Antigen
Language	English
Publishing date	2023-02-21
Publishing country	England
Document type	Journal Article
ZDB-ID	131914-0
ISSN	1365-2559 ; 0309-0167
ISSN (online)	1365-2559
ISSN	0309-0167
DOI	10.1111/his.14869
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1328: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Intensive endoscopic therapy for untreated cervical anastomotic strictures after esophagectomy: a pilot study.

van Halsema, Emo E / Bergman, Jacques J G H M / van Sandick, Johanna W / van Berge Henegouwen, Mark I / Cats, Annemieke / Veenhof, Alexander A F A / van Hooft, Jeanin E / van Dieren, Jolanda M

Surgical endoscopy

2022 Volume 37, Issue 3, Page(s) 2029–2034

Abstract: Background: Cervical anastomotic strictures after esophagectomy cause significant disease burden. We aimed to study the technical feasibility and safety of intensive endoscopic therapy.: Methods: In this pilot study, we included 15 patients with an ... ...

Abstract	Background: Cervical anastomotic strictures after esophagectomy cause significant disease burden. We aimed to study the technical feasibility and safety of intensive endoscopic therapy. Methods: In this pilot study, we included 15 patients with an untreated benign cervical anastomotic stricture after esophagectomy. Intensive endoscopic therapy comprised three endoscopic modalities: in- and excision using a needle-knife, intralesional steroid injections and bougie dilation. In two endoscopic procedures, the stricture was dilated up to a luminal diameter of 18 mm. Patients were followed up to 6 months. Results: A luminal diameter of 18 mm was achieved in 13 of 15 patients (87%) after two endoscopic procedures. No major adverse events related to the investigational treatment occurred. Median dysphagia scores significantly improved from 2 (IQR, interquartile range, 2-3) at baseline to 0 (IQR 0-1) after 14 days (p < 0.001). Eleven (73%) patients developed recurrent symptoms of dysphagia requiring a median of 1 (IQR 0-3) additional endoscopic dilation procedure. Conclusions: Achieving a luminal diameter of 18 mm in two procedures with intensive endoscopic therapy was technically feasible and effective in reducing dysphagia rapidly in patients with a cervical anastomotic stricture after esophagectomy. No major adverse events related to the investigational treatment were observed.
MeSH term(s)	Humans ; Esophagectomy/adverse effects ; Esophagectomy/methods ; Constriction, Pathologic/etiology ; Pilot Projects ; Deglutition Disorders/etiology ; Deglutition Disorders/therapy ; Esophageal Stenosis/etiology ; Esophageal Stenosis/therapy ; Treatment Outcome ; Anastomosis, Surgical/adverse effects ; Anastomosis, Surgical/methods ; Dilatation/methods ; Retrospective Studies
Language	English
Publishing date	2022-10-25
Publishing country	Germany
Document type	Journal Article
ZDB-ID	639039-0
ISSN	1432-2218 ; 0930-2794
ISSN (online)	1432-2218
ISSN	0930-2794
DOI	10.1007/s00464-022-09731-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2214: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Cytomegalovirus in Steroid-Refractory Immune Checkpoint Inhibition-Related Colitis.

van Turenhout, Sietze T / Berghuis, Marieke / Snaebjornsson, Petur / Wilgenhof, Sofie / Burgers, J A / Haanen, John B A G / van Dieren, Jolanda M

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

2019 Volume 15, Issue 1, Page(s) e15–e20

MeSH term(s)	Colitis/chemically induced ; Colitis/drug therapy ; Cytomegalovirus ; Humans ; Immune Checkpoint Inhibitors ; Lung Neoplasms ; Steroids/therapeutic use
Chemical Substances	Immune Checkpoint Inhibitors ; Steroids
Language	English
Publishing date	2019-10-31
Publishing country	United States
Document type	Letter
ZDB-ID	2432037-7
ISSN	1556-1380 ; 1556-0864
ISSN (online)	1556-1380
ISSN	1556-0864
DOI	10.1016/j.jtho.2019.07.026
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6664: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 652: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

van Leerdam, Monique E / Haanen, John B A G / Schumacher, Ton N / Voest, Emile E / Chalabi, Myriam

Nature medicine

2024 Volume 30, Issue 2, Page(s) 519–530

Abstract: Gastric and gastroesophageal junction (G/GEJ) cancers carry a poor prognosis, and despite recent advancements, most patients die of their disease. Although immune checkpoint blockade became part of the standard-of-care for patients with metastatic G/GEJ ... ...

Abstract	Gastric and gastroesophageal junction (G/GEJ) cancers carry a poor prognosis, and despite recent advancements, most patients die of their disease. Although immune checkpoint blockade became part of the standard-of-care for patients with metastatic G/GEJ cancers, its efficacy and impact on the tumor microenvironment (TME) in early disease remain largely unknown. We hypothesized higher efficacy of neoadjuvant immunotherapy plus chemotherapy in patients with nonmetastatic G/GEJ cancer. In the phase 2 PANDA trial, patients with previously untreated resectable G/GEJ tumors (n = 21) received neoadjuvant treatment with one cycle of atezolizumab monotherapy followed by four cycles of atezolizumab plus docetaxel, oxaliplatin and capecitabine. Treatment was well tolerated. There were grade 3 immune-related adverse events in two of 20 patients (10%) but no grade 4 or 5 immune-related adverse events, and all patients underwent resection without treatment-related delays, meeting the primary endpoint of safety and feasibility. Tissue was obtained at multiple time points, allowing analysis of the effects of single-agent anti-programmed cell death ligand 1 (PD-L1) and the subsequent combination with chemotherapy on the TME. Twenty of 21 patients underwent surgery and were evaluable for secondary pathologic response and survival endpoints, and 19 were evaluable for exploratory translational analyses. A major pathologic response (≤10% residual viable tumor) was observed in 14 of 20 (70%, 95% confidence interval 46-88%) patients, including 9 (45%, 95% confidence interval 23-68%) pathologic complete responses. At a median follow-up of 47 months, 13 of 14 responders were alive and disease-free, and five of six nonresponders had died as a result of recurrence. Notably, baseline anti-programmed cell death protein 1 (PD-1)
MeSH term(s)	Humans ; Neoadjuvant Therapy ; Programmed Cell Death 1 Receptor ; Adenocarcinoma/drug therapy ; Adenocarcinoma/pathology ; Stomach Neoplasms/drug therapy ; Stomach Neoplasms/pathology ; Esophagogastric Junction/pathology ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Tumor Microenvironment ; Esophageal Neoplasms ; Antibodies, Monoclonal, Humanized
Chemical Substances	atezolizumab (52CMI0WC3Y) ; Programmed Cell Death 1 Receptor ; Antibodies, Monoclonal, Humanized
Language	English
Publishing date	2024-01-08
Publishing country	United States
Document type	Clinical Trial, Phase II ; Journal Article
ZDB-ID	1220066-9
ISSN	1546-170X ; 1078-8956
ISSN (online)	1546-170X
ISSN	1078-8956
DOI	10.1038/s41591-023-02758-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4212: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 39: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito